Keros Therapeutics, Inc. Stock Price, News & Analysis

Keros Therapeutics, Inc. (KROS) has successfully closed a public offering of 2,990,000 shares of common stock at $50.00 each, generating $149.5 million in gross proceeds. This offering included the full exercise of the underwriters' option to purchase an additional 390,000 shares. The offering was managed by Jefferies LLC, SVB Leerink LLC, and Piper Sandler & Co. The proceeds will be used to advance Keros’ clinical programs, including its lead product candidates KER-050, KER-047, and KER-012, which target hematological and musculoskeletal disorders.

Keros Therapeutics, a clinical-stage biopharmaceutical company, will have its President and CEO, Jasbir S. Seehra, present at the Jefferies Virtual London Healthcare Conference on November 18 at 9:05 am ET. The event will be webcast live and archived on the company's website for 90 days. Keros focuses on developing treatments for hematological and musculoskeletal disorders with high unmet medical needs, including its lead product candidates KER-050, KER-047, and KER-012, targeting conditions like anemia and osteoporosis.

Keros Therapeutics, Inc. (Nasdaq: KROS) announced a public offering of 2,600,000 shares at $50.00 each, aiming to raise $130 million before expenses. The offering, managed by Jefferies LLC, SVB Leerink LLC, and Piper Sandler & Co., is set to close on November 17, 2020. The company also granted underwriters a 30-day option for an additional 390,000 shares. Keros focuses on developing novel treatments for hematological and musculoskeletal disorders, with lead candidates including KER-050 and KER-047 targeting conditions like anemia and bone loss.

Keros Therapeutics (Nasdaq: KROS) announced a proposed underwritten public offering of 2,250,000 shares of common stock, with an option for underwriters to purchase an additional 337,500 shares. Pricing details are yet to be determined, as the offering is subject to market conditions. Jefferies LLC, SVB Leerink LLC, and Piper Sandler & Co. are managing the offering, while a registration statement has been filed with the SEC but is not yet effective. Keros focuses on developing treatments for hematological and musculoskeletal disorders.

Keros Therapeutics (KROS) reported Q3 2020 financial results and a business update, achieving a milestone by dosing first patients in its Phase 2 clinical trial for KER-050, targeting myelodysplastic syndromes. The company regained worldwide rights to metabolic disease programs following the termination of its collaboration with Novo Nordisk, effective April 2021. Keros reported a net loss of $12.0 million for Q3 2020, up from $3.5 million in Q3 2019, driven by increased R&D and administrative expenses. Cash reserves at the end of Q3 stood at $133.8 million, projected to sustain operations into late 2022.

Keros Therapeutics (Nasdaq: KROS) announced four abstracts related to its KER-050 and KER-047 programs will be presented at the virtual 62^nd American Society of Hematology Annual Meeting from December 5-8, 2020. Key presentations include:
1. KER-050's role in promoting erythroid differentiation (Publication Number: 2736).
2. KER-050 alleviating cytopenia (Publication Number: 2582).
3. KER-047's effects on serum iron (Publication Number: 769).
4. KER-047 inhibiting ALK2 signaling (Publication Number: 771). These programs target significant hematological disorders with high unmet medical needs.

Keros Therapeutics has initiated a Phase 2 clinical trial for KER-050, targeting anemia and thrombocytopenia in patients with myelodysplastic syndromes (MDS). The first two participants have been dosed, with initial data expected by mid-2021. This open-label trial aims to confirm KER-050's safety and tolerability in patients with varying risks of MDS. Results from prior Phase 1 trials showed a robust hematological response in healthy volunteers. KER-050 could potentially address the significant unmet medical needs in MDS, affecting up to 170,000 patients annually in the U.S.

Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced that CEO Jasbir S. Seehra, Ph.D., will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 10:30 am ET. Keros specializes in developing novel treatments for hematological and musculoskeletal disorders with high unmet needs. Its lead candidates include KER-050 for cytopenias, KER-047 for anemia and fibrodysplasia ossificans progressiva, and KER-012 for bone loss disorders and pulmonary arterial hypertension.

Keros Therapeutics, Inc. (Nasdaq: KROS) announced positive preclinical results for KER-012 during the ASBMR 2020 Annual Meeting. KER-012, an activin receptor type II ligand trap, significantly increased trabecular bone volume in mice by reducing catabolism and enhancing anabolism. Key findings showed an 82.0% rise in bone volume and significant increases in trabecular thickness and formation rates. KER-012 aims to address conditions like osteoporosis, with potential implications for treating cancer-induced bone loss. CEO Jasbir S. Seehra highlighted the unique mechanism of KER-012 as a significant advancement in bone health treatments.